A

Apontis Pharma AG
XETRA:APPH

Watchlist Manager
Apontis Pharma AG
XETRA:APPH
Watchlist
Price: 9.64 EUR -1.43% Market Closed
Market Cap: 80.3m EUR
Have any thoughts about
Apontis Pharma AG?
Write Note

Wall Street
Price Targets

APPH Price Targets Summary
Apontis Pharma AG

Wall Street analysts forecast APPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for APPH is 13.52 EUR with a low forecast of 10.1 EUR and a high forecast of 17.85 EUR.

Lowest
Price Target
10.1 EUR
5% Upside
Average
Price Target
13.52 EUR
40% Upside
Highest
Price Target
17.85 EUR
85% Upside
Apontis Pharma AG Competitors:
Price Targets
600566
Hubei Jumpcan Pharmaceutical Co Ltd
88% Upside
4523
Eisai Co Ltd
56% Upside
603456
Zhejiang Jiuzhou Pharmaceutical Co Ltd
40% Upside
4536
Santen Pharmaceutical Co Ltd
28% Upside
OGI
OrganiGram Holdings Inc
76% Upside
ZVRA
Zevra Therapeutics Inc
123% Upside
ASRT
Assertio Holdings Inc
229% Upside
002422
Sichuan Kelun Pharmaceutical Co Ltd
41% Upside

Revenue
Forecast

Revenue Estimate
Apontis Pharma AG

For the last 3 years the compound annual growth rate for Apontis Pharma AG's revenue is -2%. The projected CAGR for the next 3 years is 25%.

-2%
Past Growth
25%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Apontis Pharma AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-20%
Average Miss

Net Income
Forecast

Net Income Estimate
Apontis Pharma AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is APPH's stock price target?
Price Target
13.52 EUR

According to Wall Street analysts, the average 1-year price target for APPH is 13.52 EUR with a low forecast of 10.1 EUR and a high forecast of 17.85 EUR.

What is Apontis Pharma AG's Revenue forecast?
Projected CAGR
25%

For the last 3 years the compound annual growth rate for Apontis Pharma AG's revenue is -2%. The projected CAGR for the next 3 years is 25%.

Back to Top